Abstract
Sulphasalazine (SASP) is now becoming established as a second-line agent in the treatment of rheumatoid arthritis (RA), and has been suggested as a safe drug for prolonged therapyl. This report describes reasons for discontinuation of SASP therapy in 120 patients with inflammatory forms of arthritis (RA, 108 and seronegative spondylarthritides, 12) during the first year of SASP treatment. Enteric-coated SASP was commenced at 0.5 g/day and increased weekly by 0.5 g/day to the allocated dose (1.5 g/day in 25 and 2 g/day in 95) or until dose-related side-effects occurred. Actual daily doses achieved at 6 months and continued to 12 months were 1.5 g (19%) and 2.0 g (55%).
This a summary of a poster presentation
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Reference
Bax, DE and Amos, RS (1985). Ann Rheum Dis, 44, 194 P
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 MTP Press Limited
About this chapter
Cite this chapter
Farr, M., Scott, D.G.I., Bacon, P.A. (1987). Side-effect profile of sulphasalazine in inflammatory arthritis. In: Rainsford, K.D., Velo, G.P. (eds) Side-Effects of Anti-Inflammatory Drugs. Inflammation and Drug Therapy Series, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-9775-8_30
Download citation
DOI: https://doi.org/10.1007/978-94-010-9775-8_30
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-9777-2
Online ISBN: 978-94-010-9775-8
eBook Packages: Springer Book Archive